{"title":"肺栓塞后的抗凝管理","authors":"Joseph J. Naoum","doi":"10.14797/mdcvj.1338","DOIUrl":null,"url":null,"abstract":"Pulmonary embolus (PE) carries a significant impending morbidity and mortality, especially in intermediate and high-risk patients, and the choice of initial anticoagulation that allows for therapeutic adjustment or manipulation is important. The preferred choice of anticoagulation management includes direct oral anticoagulants. Vitamin K antagonists and low-molecular-weight heparin are preferred in special populations or selected patients such as breastfeeding mothers, those with end-stage renal disease, or obese patients, among others. This article reviews the primary and longer-term considerations for anticoagulation management in patients with PE and highlights special patient populations and risk factor considerations.","PeriodicalId":39207,"journal":{"name":"Methodist DeBakey cardiovascular journal","volume":"33 12","pages":"27 - 35"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anticoagulation Management Post Pulmonary Embolism\",\"authors\":\"Joseph J. Naoum\",\"doi\":\"10.14797/mdcvj.1338\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pulmonary embolus (PE) carries a significant impending morbidity and mortality, especially in intermediate and high-risk patients, and the choice of initial anticoagulation that allows for therapeutic adjustment or manipulation is important. The preferred choice of anticoagulation management includes direct oral anticoagulants. Vitamin K antagonists and low-molecular-weight heparin are preferred in special populations or selected patients such as breastfeeding mothers, those with end-stage renal disease, or obese patients, among others. This article reviews the primary and longer-term considerations for anticoagulation management in patients with PE and highlights special patient populations and risk factor considerations.\",\"PeriodicalId\":39207,\"journal\":{\"name\":\"Methodist DeBakey cardiovascular journal\",\"volume\":\"33 12\",\"pages\":\"27 - 35\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Methodist DeBakey cardiovascular journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14797/mdcvj.1338\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Methodist DeBakey cardiovascular journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14797/mdcvj.1338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
肺栓塞(PE)的发病率和死亡率都很高,尤其是中高危患者,因此选择可进行治疗调整或操作的初始抗凝治疗非常重要。抗凝治疗的首选方案包括直接口服抗凝剂。特殊人群或特定患者,如哺乳期母亲、终末期肾病患者或肥胖患者等,首选维生素 K 拮抗剂和低分子量肝素。本文回顾了 PE 患者抗凝治疗的首要考虑因素和长期考虑因素,并重点介绍了特殊患者群体和风险因素考虑因素。
Anticoagulation Management Post Pulmonary Embolism
Pulmonary embolus (PE) carries a significant impending morbidity and mortality, especially in intermediate and high-risk patients, and the choice of initial anticoagulation that allows for therapeutic adjustment or manipulation is important. The preferred choice of anticoagulation management includes direct oral anticoagulants. Vitamin K antagonists and low-molecular-weight heparin are preferred in special populations or selected patients such as breastfeeding mothers, those with end-stage renal disease, or obese patients, among others. This article reviews the primary and longer-term considerations for anticoagulation management in patients with PE and highlights special patient populations and risk factor considerations.